Details.
Private specialist Xolair, also known as omalizumab, treatment for chronic spontaneous urticaria and associated angioedema in patients over 12 years whose symptoms have not responded adequately to antihistamines. Includes suitability assessment, personalised dosing based on age, weight and IgE levels, subcutaneous injections every 2 to 4 weeks, safety monitoring, treatment response evaluation and coordination with the existing allergy management plan. The first treatment requires observation for up to 2 hours, with subsequent appointments generally requiring 30 minutes of observation.